We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Crystal Structure Reveals How Neutralizing Antibody Blocks Astrovirus Infection

By Gerald M. Slutzky, PhD
Posted on 08 Dec 2016
Print article
Image: Neutralizing antibodies bind to a structure known as the astrovirus capsid spike domain, which projects from the surface of astrovirus particles. By binding to the spike domain, the antibodies block the virus\'s ability to attach to and infect human cells (Photo courtesy of Walter Bogdanoff, University of California, Santa Cruz).
Image: Neutralizing antibodies bind to a structure known as the astrovirus capsid spike domain, which projects from the surface of astrovirus particles. By binding to the spike domain, the antibodies block the virus\'s ability to attach to and infect human cells (Photo courtesy of Walter Bogdanoff, University of California, Santa Cruz).
A team of molecular virologists used X-ray crystallography to establish how a neutralizing antibody bound to the surface of the gastroenteritis-causing astrovirus and blocked its entry into uninfected cells.

Human astroviruses (HAstVs) are a leading cause of viral diarrhea in young children, the immune compromised, and the elderly. There are no vaccines or antiviral therapies against HAstV disease. Several lines of evidence point to the presence of protective antibodies in healthy adults as a mechanism governing protection against reinfection by HAstV. However, development of anti-HAstV therapies has been hampered by the gap in knowledge of protective antibody epitopes on the HAstV capsid surface.

To better understand how neutralizing antibodies bind to HAstV, investigators at the University of California, Santa Cruz (USA) used X-ray crystallography to examine the structure of the HAstV capsid spike domain bound to the neutralizing monoclonal antibody PL-2.

The investigators reported in the November 2, 2016, online edition of the Journal of Virology that the antibody used all six complement-determining regions to bind to a quaternary epitope on each side of the dimeric capsid spike. Furthermore, the investigators determined that the HAstV capsid spike was a receptor-binding domain and that the antibody neutralized HAstV by blocking virus attachment to cells.

These findings suggested that a subunit-based vaccine focusing the immune system on the HAstV capsid spike domain could be effective in protecting children against HAstV disease.

"We have identified a site of vulnerability on the surface of the virus that we can now target for development of a vaccine or antiviral therapy," said senior author Dr. Rebecca DuBois, assistant professor of biomolecular engineering at the University of California, Santa Cruz. "These are the first results showing how a neutralizing antibody blocks this virus. Antibody therapeutics is a rapidly growing field. Many immunotherapies are being developed to target cancer cells, and we expect to see a growing number of antibody therapies for infectious diseases over the next ten years."

Related Links:
University of California, Santa Cruz

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.